{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Metral M"],"funding":["Swiss National Science Foundation"],"pagination":["342-348"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7216878"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(5)"],"pubmed_abstract":["Objectives
Diagnosing neurocognitive impairment (NCI) in HIV infection requires time-consuming neuropsychological assessment. Screening tools are needed to identify when neuropsychological referral is indicated. We examined the positive and negative predictive values (PPVs and NPVs, respectively) of the three European AIDS Clinical Society (EACS) screening questions in identifying NCI.Methods
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study recruited patients aged ≥45 years enrolled in the Swiss HIV Cohort Study between 1 May 2013 and 30 November 2016. NAMACO participants (1) answered EACS screening questions, (2) underwent standardized neuropsychological assessment and (3) completed self-report forms [Center for Epidemiologic Studies Depressio"],"journal":["HIV medicine"],"pubmed_title":["How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?"],"pmcid":["PMC7216878"],"funding_grant_id":["163348"],"pubmed_authors":["Sacco L","Anagnostopoulos A","Fruh S","Brugger P","Muller N","Dollenmaier G","Clarke S","Bertschi M","Elzi L","Battegay M","Vernazza P","Gunthard HF","Meuli R","Metzner KJ","Huber M","Trkola A","Calmy A","Darling K","Yerly S","Tarr P","Nicca D","Hundsberger T","Fehr J","Kahlert CR","Nadin I","Braun DL","Hosli I","Speck R","Schneitter M","Kunze U","Ledergerber B","Doco Lecompte T","Rauch A","Aebi-Popp K","Du Pasquier R","Derfuss T","Monsch AU","Bruno A","Schmid P","Alves D","Paioni P","Di Benedetto C","Metral M","Hirsch HH","Scherrer AU","Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study group, Swiss HIV Cohort Study","Hoffmann M","Hauser C","Bernasconi E","Keiser O","Hasse B","Simioni S","Krueger G","Assal F","Granziera C","Furrer H","Marzolini C","Pantaleo G","Stockle M","von Arx S","Egger M","Fellay J","Perreau M","Wandeler G","Haerry D","Cavassini M","Gutbrod K","Vargas M","Kaiser L","Fux C","Decosterd L","Tarr PE","Cusini A","Bucher HC","Eisele G","Stoeckle M","Ciuffi A","Fux CA","Martinetti G","Scherrer A","Pignatti R","Rudin C","Schwind M","Pasquier RD","Kouyos RD","Locatelli I","Martinez de Tejada B","Kovari H","Vallet Y","Boni J","Klimkait T","Weber R"],"additional_accession":[]},"is_claimable":false,"name":"How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?","description":"Objectives
Diagnosing neurocognitive impairment (NCI) in HIV infection requires time-consuming neuropsychological assessment. Screening tools are needed to identify when neuropsychological referral is indicated. We examined the positive and negative predictive values (PPVs and NPVs, respectively) of the three European AIDS Clinical Society (EACS) screening questions in identifying NCI.Methods
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study recruited patients aged ≥45 years enrolled in the Swiss HIV Cohort Study between 1 May 2013 and 30 November 2016. NAMACO participants (1) answered EACS screening questions, (2) underwent standardized neuropsychological assessment and (3) completed self-report forms [Center for Epidemiologic Studies Depressio","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2025-04-27T00:25:37.879Z","creation":"2020-05-22T20:01:18Z"},"accession":"S-EPMC7216878","cross_references":{"pubmed":["31883203"],"doi":["10.1111/hiv.12828"]}}